|
Prescription Drug Search
Strengths available for Bivalirudin vial:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about CancerDrugsDirect.com
List of countries where we can ship Bivalirudin:
- Armenia
- Australia
- Barbados
- Belgium
- Bermuda
- Bolivia
- Bosnia and Herzegovina
- Bulgaria
- Colombia
- Croatia
- Cuba
- Gibraltar
- Greece
- India
- Indonesia
- Iran
- Italy
- Korea, Republic of
- Kuwait
- Luxembourg
- Moldova, Republic of
- Morocco
- Netherlands Antilles
- Nicaragua
- Panama
- Russian Federation
- Saint Lucia
- Saudi Arabia
- Singapore
- Slovenia
- Spain
- Taiwan
- Thailand
- Tonga
- Trinidad and Tobago
- Ukraine
- United Arab Emirates
- United Kingdom, UK
- United States, US
- Uzbekistan
Latest news releases on Bivalirudin:
Bivalirudin and post-cardiotomy ECMO: a word of caution - 7thspace.com
Bivalirudin has been proposed as the sole anticoagulant in patients under extracorporeal membrane oxygenation (ECMO) or cardiopulmonary bypass. Due to the pharmacodynamic properties of bivalirudin, areas of blood stagnation should be carefully avoided to ...
Post-PCI Bleeds Drop with Shifts in Drug Strategy - MedPage Today
For example, the use of bivalirudin (Angiomax) increased from 17% to 30%, while employing heparin plus glycoprotein IIb/IIIa inhibitors (GPI) decreased from 41% to 28%, mostly driven by the use of bivalirudin-only in the UA/NSTEMI and elective PCI groups.
Definition, Incidence & Location, Predictors, & Implications of Gastrointestinal Bleeding following PCI - Medscape News
[8,9,11,13,16] A randomized double-blind trial of bivalirudin versus a glycoprotein IIb/IIIa inhibitor plus UFH administered at the time of PCI [21] demonstrated comparatively low rates of GI bleeding (0.1 vs 0.3%, respectively), most likely due to the ...
Outcomes Worse for Inhospital Stent Thrombosis - MedPage Today
The patients were randomized to bivalirudin alone or to unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. During about 3 years of follow-up, 4.9% of the patients developed Academic Research Consortium definite or probable stent ...
